Beauty Health (NASDAQ:SKIN) Releases Earnings Results, Beats Expectations By $0.04 EPS

Beauty Health (NASDAQ:SKIN) posted its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04, Zacks reports. Beauty Health had a negative return on equity of 15.40% and a negative net margin of 3.16%.The company had revenue of $64.91 million for the quarter, compared to the consensus estimate of $66.28 million.

Here are the key takeaways from Beauty Health’s conference call:

• Device placements were weaker than expected, prompting a revised full-year revenue outlook to $280 million–$295 million (about a 2.5% reduction); management says Q2 softness will likely persist while commercial fixes take time to translate to results.
• Q1 adjusted EBITDA outperformed at $8.5 million (up 17% YoY) with an adjusted gross margin of 72.2%, and the company is maintaining its full-year adjusted EBITDA guidance of $35M–$45M.
• The active installed base grew to 36,400 devices (up 4% YoY) and device churn declined ~40% YoY, signaling improved provider retention and resilience in recurring consumables revenue.
• Management is enacting commercial and leadership changes (CEO taking a direct sales role and three new independent directors) and advancing an innovation roadmap — relaunching Keravive next quarter, a clinically backed booster in Q4, strategic partnerships, and a next?gen Hydrafacial targeted for 2028 — initiatives that are promising but expected to take time to impact growth.

Beauty Health Price Performance

Shares of NASDAQ SKIN traded down $0.33 during mid-day trading on Friday, reaching $0.58. The company had a trading volume of 4,762,649 shares, compared to its average volume of 726,749. The company has a current ratio of 1.66, a quick ratio of 1.40 and a debt-to-equity ratio of 3.94. The stock has a market cap of $74.11 million, a PE ratio of -2.90 and a beta of 1.12. The company has a 50-day moving average price of $0.98 and a two-hundred day moving average price of $1.24. Beauty Health has a 1-year low of $0.57 and a 1-year high of $2.69.

Hedge Funds Weigh In On Beauty Health

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. grew its holdings in shares of Beauty Health by 65.4% in the 4th quarter. Invesco Ltd. now owns 69,422 shares of the company’s stock worth $96,000 after acquiring an additional 27,453 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Beauty Health by 127.0% in the 4th quarter. Millennium Management LLC now owns 5,764,802 shares of the company’s stock worth $8,013,000 after acquiring an additional 3,225,668 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Beauty Health by 270.1% in the 4th quarter. AQR Capital Management LLC now owns 333,196 shares of the company’s stock worth $463,000 after acquiring an additional 243,179 shares during the last quarter. Atom Investors LP acquired a new position in shares of Beauty Health in the 4th quarter worth $29,000. Finally, Squarepoint Ops LLC grew its holdings in shares of Beauty Health by 22.6% in the 4th quarter. Squarepoint Ops LLC now owns 275,885 shares of the company’s stock worth $383,000 after acquiring an additional 50,794 shares during the last quarter. 93.26% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SKIN has been the topic of a number of research reports. TD Cowen dropped their price objective on Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a research note on Monday, March 16th. Benchmark reissued a “hold” rating on shares of Beauty Health in a research note on Friday, March 13th. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 price objective on shares of Beauty Health in a research note on Wednesday, January 14th. Canaccord Genuity Group dropped their price objective on Beauty Health from $1.50 to $1.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Finally, Zacks Research raised Beauty Health from a “strong sell” rating to a “hold” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Beauty Health currently has an average rating of “Hold” and a consensus target price of $2.32.

Beauty Health Company Profile

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.